We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics PR Newswire THOUSAND OAKS, Calif., April 16, 2021 THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday...
By Michael Dabaie Five Prime Therapeutics Inc. shares were up 78% to $37.78 in afternoon trading Thursday. Amgen Inc. agreed to acquire Five Prime Therapeutics for $38 a share in cash...
By Michael Dabaie Amgen Inc. agreed to acquire Five Prime Therapeutics for $38 a share in cash, representing an equity value of about $1.9 billion. Shares of Five Prime Therapeutics closed...
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), will report its fourth quarter and full year 2020 operational and financial results on Wednesday, March 10, 2021 after the U.S. financial markets...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions